Journal of Hepatology
Volume 48, Issue 6 , Pages 945-951 , June 2008

Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis

Received 13 December 2007 ,Revised 28 January 2008 ,Accepted 24 February 2008.

References 

  1. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–148
  2. Linderoth G, Jepsen P, Schonheyder HC, Johnsen SP, Sorensen HT. Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: A population-based cohort study. Alcohol Clin Exp Res. 2006;30:636–641
  3. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology. 1986;6:252–262
  4. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999;19:205–219
  5. Feliu E, Gougerot MA, Hakim J, Cramer E, Auclair C, Rueff B, et al. Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis. Eur J Clin Invest. 1977;7:571–577
  6. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis. 2000;182:526–533
  7. Rajkovic IA, Yousif-Kadaru AG, Wyke RJ, Williams R. Polymorphonuclear leucocyte locomotion and aggregation in patients with alcoholic liver disease. Clin Exp Immunol. 1984;58:654–662
  8. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46:831–840
  9. Campbell AC, Dronfield MW, Toghill PJ, Reeves WG. Neutrophil function in chronic liver disease. Clin Exp Immunol. 1981;45:81–89
  10. Kirsch R, Woodburne VE, Shephard EG, Kirsch RE. Patients with stable uncomplicated cirrhosis have normal neutrophil function. J Gastroenterol Hepatol. 2000;15:1298–1306
  11. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422–433
  12. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol. 2006;45:744–757
  13. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441–1449
  14. Dbouk N, McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Curr Treat Options Gastroenterol. 2006;9:464–474
  15. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007;CD005165
  16. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74:123–127
  17. D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324:1361
  18. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16:1461–1467
  19. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812–822
  20. Madsen K. Probiotics and the immune response. J Clin Gastroenterol. 2006;40:232–234
  21. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39:841–856
  22. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649
  23. Candy DC, Densham L, Lamont LS, Greig M, Lewis J, Bennett H, et al. Effect of administration of Lactobacillus casei shirota on sodium balance in an infant with short bowel syndrome. J Pediatr Gastroenterol Nutr. 2001;32:506–508
  24. Srinivasan R, Meyer R, Padmanabhan R, Britto J. Clinical safety of Lactobacillus casei shirota as a probiotic in critically ill children. J Pediatr Gastroenterol Nutr. 2006;42:171–173
  25. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 2004;10:1109–1119
  26. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care. 2006;10:R169
  27. Roilides E, Katsifa H, Tsaparidou S, Stergiopoulou T, Panteliadis C, Walsh TJ. Interleukin 10 suppresses phagocytic and antihyphal activities of human neutrophils. Cytokine. 2000;12:379–387
  28. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol. 1996;15:181–187
  29. Ferrante A, Martin AJ, Bates EJ, Kowanko IC, Harvey DP, Parsons D, et al. Interaction of Staphylococcus aureus with human neutrophils and the down-regulation of TNF receptors. J Immunol. 1994;152:3998–4004
  30. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990;172:599–607
  31. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond). 1998;94:461–471
  32. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut. 2005;54:556–563
  33. Prytz H, Holst-Christensen J, Korner B, Liehr H. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Scand J Gastroenterol. 1976;11:857–863
  34. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988;8:232–236
  35. Hurley JC, Tosolini FA, Louis WJ. Quantitative Limulus lysate assay for endotoxin and the effect of plasma. J Clin Pathol. 1991;44:849–854
  36. Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology. 2003;37:1154–1164
  37. Frances R, Benlloch S, Zapater P, Gonzalez JM, Lozano B, Munoz C, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology. 2004;39:484–491
  38. Zapater P, Frances R, Gonzalez-Navajas JM, Moreu R, Llanos L, Pascual D, et al. Presence of bacterial DNA is a new survival indicator in patients with cirrhosis and non-infected ascitic fluid. Hepatology. 2007;46:A40
  39. Parker LC, Whyte MK, Dower SK, Sabroe I. The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol. 2005;77:886–892
  40. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102:2660–2669
  41. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr. 2006;83:1256–1264

☆ The authors who have taken part in the research of this paper declared that they received funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00195-5

doi: 10.1016/j.jhep.2008.02.015

Journal of Hepatology
Volume 48, Issue 6 , Pages 945-951 , June 2008

Article Tools

* Image Usage & Resolution